化脓性汗腺炎生活质量评估:EADV工作组立场声明
本文由EADV生活质量工作组与痤疮、玫瑰痤疮及化脓性汗腺炎工作组联合制定,旨在总结HS生活质量评估现状并给出实践推荐。HS导致显著的生活质量损害,高于多数其他慢性皮肤病;已发表研究中84%使用DLQI评估。因缺乏充分验证,工作组暂不推荐HS特异性量表,推荐皮肤科特异性DLQI用于HS患者。
要点
- HS生活质量损害显著,高于多数其他慢性皮肤病。
- 已发表研究中84%使用DLQI评估HS影响。
- 暂不推荐HS特异性量表,推荐DLQI用于HS患者。
核心结论
- EADV工作组推荐皮肤科特异性DLQI问卷用于HS患者的生活质量评估。
- 因缺乏充分验证,目前暂不推荐现有的HS特异性健康相关生活质量量表用于临床研究。
研究设计与样本
- 本文为欧洲皮肤病与性病学会(EADV)生活质量与患者导向结局工作组及痤疮、玫瑰痤疮和化脓性汗腺炎工作组的联合立场声明。
主要发现
- HS导致显著的生活质量损害,高于多数其他慢性皮肤病。
- 已发表研究中84%使用皮肤病生活质量指数(DLQI)评估HS影响。
- 一项关于英夫利西单抗的双盲随机安慰剂对照试验(参与者数量少)报告治疗组健康相关生活质量改善显著优于安慰剂组。
关键数值与推荐
- 已发表研究中84%使用DLQI评估HS影响。
- 推荐DLQI用于HS患者。
- 暂不推荐HS特异性健康相关生活质量量表用于临床研究。
临床怎么用
- 在HS患者临床评估中使用DLQI问卷测量生活质量。
- 鼓励进一步开发、验证和使用其他HS特异性、皮肤科特异性及通用量表,但需基于EADV生活质量工作组既往出版物中提出的原则。
局限性
- 缺乏使用健康相关生活质量工具作为结局指标的高质量HS临床试验。
- 现有HS特异性健康相关生活质量量表缺乏充分验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This paper is organized jointly by the European Academy of Dermatology and Venereology (EADV) Task Force (TF) on Quality of Life (QoL) and Patient-Oriented Outcomes and the EADV TF on acne, rosacea and hidradenitis suppurativa (ARHS). The purpose of this paper was to present current knowledge about QoL assessment in HS, including data on HS-specific health-related (HR) QoL instruments and HRQoL changes in clinical trials, and to make practical recommendations concerning the assessment of QoL in people with HS. HS results in significant quimp that is higher than in most other chronic skin diseases. HS impact in published studies was assessed predominantly (84% of studies) by the Dermatology Life Quality Index (DLQI). There is a lack of high-quality clinical trials in HS patients where HRQoL instruments have been used as outcome measures. One double-blind randomized placebo-controlled trial on infliximab with low number of participants reported significantly better HRQoL improvement in the treatment group than in the placebo group. Well-designed clinical studies in HS patients to compare different treatment methods, including surgical methods and assessing long-term effects, are needed. Because of lack of sufficient validation, the Task Forces are not at present able to recommend existing HS-specific HRQoL instruments for use in clinical studies. The EADV TFs recommend the dermatology-specific DLQI questionnaire for use in HS patients. The EADV TFs encourage the further development, validation and use of other HS-specific, dermatology-specific and generic instruments but such use should be based on the principles presented in the previous publications of the EADV TF on QoL and Patient-Oriented Outcomes.
引用
- Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2019. PMID: 31037773. doi:10.1111/jdv.15519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。